Optiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%

MT Newswires Live

Jul 22

Optiscan Imaging (ASX:OIL) is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.

The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.

The company's shares rose 7% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2653278752"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653278752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653278752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653278752","market":"fut","top_or_hot":-1,"title":"Optiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.</p><p>The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.</p><p>The company's shares rose 7% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptiscan Imaging to Commence US Clinical Study for InVue, InForm Devices in Breast Conserving Surgery, Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-22 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.</p><p>The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.</p><p>The company's shares rose 7% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653278752","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653278752","pubTimestamp":1784685621,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optiscan Imaging  is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.The company's shares rose 7% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","OIL.AU":"OPTISCAN IMAGING LIMITED"},"translate_title":"Optiscan Imaging 将开始 InVue 的美国临床研究，为保乳手术中的设备提供信息，股价上涨 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OIL.AU":1},"content_text":"Optiscan Imaging (ASX:OIL) is set to start a US clinical study assessing the safety, performance and workflow utility of its InVue precision surgery imaging device and InForm digital pathology imaging device in patients undergoing breast-conserving surgery, according to a Wednesday Australian bourse filing.The company said the study will evaluate InVue for in vivo surgical imaging and InForm for ex vivo digital pathology imaging in 35 US patients, seeking to validate an integrated surgical-pathology workflow for US market entry and broader clinical expansion.The company's shares rose 7% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}